Aminoglycoside Forecasting in Neutropenic Patients with Cancer

Jane L. Kosirog, Raylene M. Rospond, Christopher J. Destache, Phillip Hall

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To validate the population pharmacokinetic parameters of aminoglycoside disposition in patients with cancer, a retrospective evaluation of predictive performance of a Bayesian program was performed in 155 patients from 1986 to 1989 who received amikacin, gentamicin or tobramycin. Each patient received 1 of the 3 drugs and had initial drug concentration determination, with a second set of drug concentrations drawn ⩽14 days after the initial dose. Predictions of 64 amikacin, 144 gentamicin and 102 tobramycin concentrations were generated using 1-compartment model pharmacokinetic parameters, serum creatinine values, patients’ dosage history and demographic data. The mean (± SD) observed (and predicted) serum concentrations for amikacin were 18.9 ± 14.8 mg/L (17.2 ± 14.1 mg/L); for gentamicin were 4.49 ± 3.58 mg/L (4.26 ± 3.33 mg/L) and for tobramycin were 4.52 ± 3.70 mg/L (4.05 ± 3.49 mg/L) [p > 0.05]. Results demonstrated minimal bias with a mean error in gentamicin concentrations of −0.236 (95% CI −0.533: 0.0613). Significant (p <0.05) underprediction occurred in concentrations of tobramycin [−0.474 mg/L (95% CI −0.842: −0.0107)] and amikacin [−1.77 mg/L (95% CI −3.42: −0.114)]. Good precision is indicated by a mean squared error for gentamicin of 3.35 mg/L (95% CI 1.70: 4.99) and for tobramycin of 3.64 mg/L (95% CI 1.83: 5.44). Fair precision is demonstrated by amikacin [46.1 mg/L (95% CI 27.3: 65.0)]. Similar results were shown in a separate peak/trough analysis. These data indicate that aminoglycoside pharmacokinetics in patients with cancer can be predicted with minimal bias and good precision using a Bayesian forecasting program for gentamicin and tobramycin.

Original languageEnglish
Pages (from-to)79-87
Number of pages9
JournalClinical Pharmacokinetics
Volume24
Issue number1
DOIs
StatePublished - 1993

Fingerprint

Tobramycin
Aminoglycosides
Gentamicins
Amikacin
Neoplasms
Pharmacokinetics
Pharmaceutical Preparations
Serum
Creatinine
History
Demography
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Aminoglycoside Forecasting in Neutropenic Patients with Cancer. / Kosirog, Jane L.; Rospond, Raylene M.; Destache, Christopher J.; Hall, Phillip.

In: Clinical Pharmacokinetics, Vol. 24, No. 1, 1993, p. 79-87.

Research output: Contribution to journalArticle

Kosirog, Jane L. ; Rospond, Raylene M. ; Destache, Christopher J. ; Hall, Phillip. / Aminoglycoside Forecasting in Neutropenic Patients with Cancer. In: Clinical Pharmacokinetics. 1993 ; Vol. 24, No. 1. pp. 79-87.
@article{e954f24020d14b639704499c40f66e51,
title = "Aminoglycoside Forecasting in Neutropenic Patients with Cancer",
abstract = "To validate the population pharmacokinetic parameters of aminoglycoside disposition in patients with cancer, a retrospective evaluation of predictive performance of a Bayesian program was performed in 155 patients from 1986 to 1989 who received amikacin, gentamicin or tobramycin. Each patient received 1 of the 3 drugs and had initial drug concentration determination, with a second set of drug concentrations drawn ⩽14 days after the initial dose. Predictions of 64 amikacin, 144 gentamicin and 102 tobramycin concentrations were generated using 1-compartment model pharmacokinetic parameters, serum creatinine values, patients’ dosage history and demographic data. The mean (± SD) observed (and predicted) serum concentrations for amikacin were 18.9 ± 14.8 mg/L (17.2 ± 14.1 mg/L); for gentamicin were 4.49 ± 3.58 mg/L (4.26 ± 3.33 mg/L) and for tobramycin were 4.52 ± 3.70 mg/L (4.05 ± 3.49 mg/L) [p > 0.05]. Results demonstrated minimal bias with a mean error in gentamicin concentrations of −0.236 (95{\%} CI −0.533: 0.0613). Significant (p <0.05) underprediction occurred in concentrations of tobramycin [−0.474 mg/L (95{\%} CI −0.842: −0.0107)] and amikacin [−1.77 mg/L (95{\%} CI −3.42: −0.114)]. Good precision is indicated by a mean squared error for gentamicin of 3.35 mg/L (95{\%} CI 1.70: 4.99) and for tobramycin of 3.64 mg/L (95{\%} CI 1.83: 5.44). Fair precision is demonstrated by amikacin [46.1 mg/L (95{\%} CI 27.3: 65.0)]. Similar results were shown in a separate peak/trough analysis. These data indicate that aminoglycoside pharmacokinetics in patients with cancer can be predicted with minimal bias and good precision using a Bayesian forecasting program for gentamicin and tobramycin.",
author = "Kosirog, {Jane L.} and Rospond, {Raylene M.} and Destache, {Christopher J.} and Phillip Hall",
year = "1993",
doi = "10.2165/00003088-199324010-00007",
language = "English",
volume = "24",
pages = "79--87",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Aminoglycoside Forecasting in Neutropenic Patients with Cancer

AU - Kosirog, Jane L.

AU - Rospond, Raylene M.

AU - Destache, Christopher J.

AU - Hall, Phillip

PY - 1993

Y1 - 1993

N2 - To validate the population pharmacokinetic parameters of aminoglycoside disposition in patients with cancer, a retrospective evaluation of predictive performance of a Bayesian program was performed in 155 patients from 1986 to 1989 who received amikacin, gentamicin or tobramycin. Each patient received 1 of the 3 drugs and had initial drug concentration determination, with a second set of drug concentrations drawn ⩽14 days after the initial dose. Predictions of 64 amikacin, 144 gentamicin and 102 tobramycin concentrations were generated using 1-compartment model pharmacokinetic parameters, serum creatinine values, patients’ dosage history and demographic data. The mean (± SD) observed (and predicted) serum concentrations for amikacin were 18.9 ± 14.8 mg/L (17.2 ± 14.1 mg/L); for gentamicin were 4.49 ± 3.58 mg/L (4.26 ± 3.33 mg/L) and for tobramycin were 4.52 ± 3.70 mg/L (4.05 ± 3.49 mg/L) [p > 0.05]. Results demonstrated minimal bias with a mean error in gentamicin concentrations of −0.236 (95% CI −0.533: 0.0613). Significant (p <0.05) underprediction occurred in concentrations of tobramycin [−0.474 mg/L (95% CI −0.842: −0.0107)] and amikacin [−1.77 mg/L (95% CI −3.42: −0.114)]. Good precision is indicated by a mean squared error for gentamicin of 3.35 mg/L (95% CI 1.70: 4.99) and for tobramycin of 3.64 mg/L (95% CI 1.83: 5.44). Fair precision is demonstrated by amikacin [46.1 mg/L (95% CI 27.3: 65.0)]. Similar results were shown in a separate peak/trough analysis. These data indicate that aminoglycoside pharmacokinetics in patients with cancer can be predicted with minimal bias and good precision using a Bayesian forecasting program for gentamicin and tobramycin.

AB - To validate the population pharmacokinetic parameters of aminoglycoside disposition in patients with cancer, a retrospective evaluation of predictive performance of a Bayesian program was performed in 155 patients from 1986 to 1989 who received amikacin, gentamicin or tobramycin. Each patient received 1 of the 3 drugs and had initial drug concentration determination, with a second set of drug concentrations drawn ⩽14 days after the initial dose. Predictions of 64 amikacin, 144 gentamicin and 102 tobramycin concentrations were generated using 1-compartment model pharmacokinetic parameters, serum creatinine values, patients’ dosage history and demographic data. The mean (± SD) observed (and predicted) serum concentrations for amikacin were 18.9 ± 14.8 mg/L (17.2 ± 14.1 mg/L); for gentamicin were 4.49 ± 3.58 mg/L (4.26 ± 3.33 mg/L) and for tobramycin were 4.52 ± 3.70 mg/L (4.05 ± 3.49 mg/L) [p > 0.05]. Results demonstrated minimal bias with a mean error in gentamicin concentrations of −0.236 (95% CI −0.533: 0.0613). Significant (p <0.05) underprediction occurred in concentrations of tobramycin [−0.474 mg/L (95% CI −0.842: −0.0107)] and amikacin [−1.77 mg/L (95% CI −3.42: −0.114)]. Good precision is indicated by a mean squared error for gentamicin of 3.35 mg/L (95% CI 1.70: 4.99) and for tobramycin of 3.64 mg/L (95% CI 1.83: 5.44). Fair precision is demonstrated by amikacin [46.1 mg/L (95% CI 27.3: 65.0)]. Similar results were shown in a separate peak/trough analysis. These data indicate that aminoglycoside pharmacokinetics in patients with cancer can be predicted with minimal bias and good precision using a Bayesian forecasting program for gentamicin and tobramycin.

UR - http://www.scopus.com/inward/record.url?scp=0027400260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027400260&partnerID=8YFLogxK

U2 - 10.2165/00003088-199324010-00007

DO - 10.2165/00003088-199324010-00007

M3 - Article

VL - 24

SP - 79

EP - 87

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 1

ER -